Pipeline

pipeline header image
pipeline icon

Pipeline

Kriya is developing a portfolio of one-time gene therapies to address common diseases. Our current pipeline includes three main therapeutic areas:

Therapeutic AreaProgramDiseaseMechanismDiscoveryResearchIND-EnablingClinical
Ophthalmology
KRIYA-825Geographic Atrophy Anti-C3 and C5

 
KRIYA-586Thyroid Eye Disease Anti-IGF1R Antibody

 
KRIYA-296Undisclosed Undisclosed

 
Metabolic
KRIYA-839Diabetes Insulin & Glucokinase

 
KRIYA-497MASH FGF21

 
KRIYA-652Undisclosed Undisclosed

 
Neurology
KRIYA-748Trigeminal Neuralgia Engineered Ion Channel

 
KRIYA-382Focal Epilepsy Engineered Ion Channel

 
KRIYA-454Undisclosed Undisclosed

 
Ophthalmology
DiscoveryResearchIND-EnablingClinical
Geographic Atrophy | Anti-C3 and C5
KRIYA-825
Thyroid Eye Disease | Anti-IGF1R Antibody
KRIYA-586
Undisclosed | Undisclosed
KRIYA-296
Metabolic
DiscoveryResearchIND-EnablingClinical
Diabetes | Insulin & Glucokinase
KRIYA-839
MASH | FGF21
KRIYA-497
Undisclosed | Undisclosed
KRIYA-652
Neurology
DiscoveryResearchIND-EnablingClinical
Trigeminal Neuralgia | Engineered Ion Channel
KRIYA-748
Focal Epilepsy | Engineered Ion Channel
KRIYA-382
Undisclosed | Undisclosed
KRIYA-454

Kriya’s pipeline candidates have not yet been approved as safe or effective by any regulatory authority.

Ophthalmology

Ophthalmology icon

Metabolic

Metabolic icon

Neurology

Neurology icon